Delivery Order SPE2DB22D1017-SPE2DB25FG9FE
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,438.43 on August 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages). This is a firm fixed-price, competitive award with no set-aside designation and an ultimate completion date of August 11, 2025. The place of performance is the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $24,690.56 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award to the pharmaceutical distributor for delivery to the Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $7,403.14 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). This competitively awarded, firm fixed-price contract is not designated as a set-aside and specifies a place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 22, 2025. The contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply framework with the...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 30, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $77,218.07. This is a firm fixed price, non-competitive delivery order to be completed by July 31, 2025. The contract is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,466.25 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 count). This is a firm fixed-price delivery order with no set-aside designation, executed through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract valued at $3,513.96, with an ultimate completion date of August 11, 2025. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg with a ceiling value of $5,936.37. This competitively awarded, firm fixed-price delivery order was issued on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract represents a pharmaceutical supply fulfillment supporting federal medical procurement needs, with performance occurring at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $6,799.69. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through the DLA's open procurement process. The order is scheduled for completion by August 8, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,065.14 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract. The order was competitively awarded without set-aside provisions and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken,...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9FEDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,869.31 for 60 tablets of Xifaxan 550 mg on August 7, 2025, with an ultimate completion date of August 8, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and healthcare commodities to support military and federal healthcare programs globally. The contract demonstrates AmerisourceBergen's established role as a critical pharmaceutical distributor within the federal medical supply chain, serving the Defense Health Agency and other government healthcare systems through flexible delivery order mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 8/7/25 |